- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
July 22, 2024Seven Robins Kaplan Attorneys Named to Minnesota Lawyer’s Power 30: Personal Injury List
-
July 18, 2024Emily Niles Named to Law360’s Top Attorneys Under 40
-
July 16, 2024David Martinez Named To 2024 Leaders of Influence: Litigators & Trial Attorneys by Los Angeles Business Journal
-
August 6, 2024Identifying Opportunities: Affirmative Recovery Strategies
-
August 15, 2024Annual Robins Kaplan MAJ Welcome Reception
-
October 20, 2024License Agreement Disputes:
-
July 24, 2024Navigating Copyright Act Section 117 in Software Licensing and Litigation
-
Second QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin
-
July 15, 2024Making The Whole Truth Public
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
IP: Generic Manufacturers Win In The Supreme Court
The Supreme Court overruled the Federal Circuit, ruling that generic manufacturers can use counterclaims to force corrections of patent use codes.
July 17, 2012
This spring the Supreme Court seems to have made it easier for generic drug manufacturers to contest the reach of patent protection for brand name drugs. In Caraco Pharmaceutical Labs, Ltd. v. Novo Nordisk, the Supreme Court ruled that a congressionally-created counterclaim allows generic manufacturers to challenge the exact uses a drug patent covers. Generic manufacturers can use the counterclaim in cases where a patent holder asserts infringement in response to an application to manufacture a generic version of a brand-name drug (i.e., Abbreviated New Drug Application or ANDA).
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
Related Professionals
Bryan J. Vogel
Partner
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.